Skip to main content
. 2015 Jan 26;18(4):pyu077. doi: 10.1093/ijnp/pyu077

Figure 3.

Figure 3.

Role of TrkB and mTORC1 in the antidepressant action of 7,8-DHF and ANA-12 on LPS-induced depression-like behavior. (A–C) The schedule of treatment and behavioral evaluations. (D) Locomotion, (E) TST, and (F) FST tests. Values represent the mean ± standard error of the mean (SEM). n = 8–10 for D, E, and F. **p < 0.01, ***p < 0.001 compared with the LPS + vehicle group. ## p < 0.01 compared with the LPS + 7,8-DHF + ANA-12 group. N.S.: not significant. (G) TST and (H) FST. Bilateral infusion of ANA-12 into the NAc significantly attenuated the increase of immobility time of LPS-treated mice. Values represent the mean ± SEM. n = 7 for (G) and (H). *p < 0.05, **p < 0.01 compared with the LPS + vehicle group. (I): TST, (J): FST. I.c.v. infusion of rapamycin significantly blocked the decrease of immobility time of LPS-treated mice by 7,8-DHF. In contrast, i.c.v. infusion of rapamycin did not affect the decrease of immobility time of LPS-treated mice by ANA-12. Values represent the mean ± SEM (n = 8 – 10). **p < 0.01, ***p < 0.001 compared with the LPS + vehicle group. ## p < 0.01 compared with the LPS + 7,8-DHF group. N.S.: not significant. TrkB: tropomyosin-receptor-kinase B; mTORC1: mammalian target of rapamycin complex 1; 7,8-DHF:7,8-dihydroxyflavone; TST: tail suspension test; FST: forced swimming test; NAc: nucleus accumbens; i.c.v.: intracerebroventricular.